Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier stage pipeline forward. The company faces a critical transition period as it approaches an exclusivity cliff for cabozantinib, which currently accounts for 91% of total revenue.
Cyborg Score Rationale
Exelixis demonstrated strong commercial momentum with 17% net product revenue growth to $2.1 billion, underpinned by a 16% increase in volume. However, the company faces significant near-term patent cliff risk. The core composition of matter patent for the franchise is set to expire in August 2026. Success of zanzalintinib as a successor product is critical.
Top Insights
Current market cap is $11.4B with 260M shares.
The FDA has accepted a New Drug Application for zanzalintinib in colorectal cancer with a PDUFA action date of December 3, 2026.
A growing challenge for the company is the erosion of net margins through gross-to-net deductions. Discounts and allowances rose 25% to $889 million, representing 30% of gross product revenues.
Supported by $1.7 billion in cash and zero debt, the company has aggressively returned capital to shareholders, repurchasing $1.2 billion in stock since August 2024.
Named Competitors
Sutent (sunitinib) — Multi-kinase inhibitor for renal cell carcinoma
Nexavar (sorafenib) — Multi-kinase inhibitor for hepatocellular carcinoma and thyroid cancer
Tecentriq (atezolizumab) — PD-L1 inhibitor used in combination with Exelixis therapies
Recent Developments
(February 2026) Fourth quarter and full-year 2025 financial results released showing $2.32B revenue and strong cabozantinib growth
(January 2026) Provided 2026 guidance of $2.325-$2.425B net product revenues and announced key clinical milestones including STELLAR-303, STELLAR-304, and STELLAR-316 trials
(December 2025) Merck initiated LITESPARK-033 pivotal trial of zanzalintinib in combination with belzutifan in renal cell carcinoma under clinical collaboration
Open the full interactive Exelixis, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.